1. Home
  2. CWCO vs GYRE Comparison

CWCO vs GYRE Comparison

Compare CWCO & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Consolidated Water Co. Ltd.

CWCO

Consolidated Water Co. Ltd.

HOLD

Current Price

$33.78

Market Cap

581.2M

Sector

Utilities

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$7.58

Market Cap

679.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CWCO
GYRE
Founded
1973
2002
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Water Supply
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
581.2M
679.4M
IPO Year
1997
2004

Fundamental Metrics

Financial Performance
Metric
CWCO
GYRE
Price
$33.78
$7.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$40.00
$17.00
AVG Volume (30 Days)
111.6K
52.9K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
1.66%
N/A
EPS Growth
N/A
N/A
EPS
1.14
0.02
Revenue
$132,073,368.00
$275,000.00
Revenue This Year
$4.34
$19.88
Revenue Next Year
$42.86
N/A
P/E Ratio
$29.61
$372.50
Revenue Growth
N/A
N/A
52 Week Low
$22.69
$6.58
52 Week High
$39.12
$11.77

Technical Indicators

Market Signals
Indicator
CWCO
GYRE
Relative Strength Index (RSI) 49.49 51.60
Support Level $32.78 $7.25
Resistance Level $34.39 $7.91
Average True Range (ATR) 0.99 0.26
MACD 0.08 0.01
Stochastic Oscillator 45.59 52.14

Price Performance

Historical Comparison
CWCO
GYRE

About CWCO Consolidated Water Co. Ltd.

Consolidated Water Co Ltd is a water utility company. It develops and operates seawater desalination plants and water distribution systems. The company's business segments are; The retail segment operates the water utility for the Seven Mile Beach and West Bay areas of Grand Cayman Island, The bulk segment supplies potable water to government utilities in Grand Cayman and The Bahamas under long-term contracts, The services segment designs, constructs and sells water infrastructure and provides management and operating services to third parties. The manufacturing segment manufactures and services a wide range of custom and specialized water-related products applicable to commercial, municipal, and industrial water production, supply, and treatment, and the corporate segment.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: